Passage Bio (NASDAQ:PASG) vs. Elevation Oncology (NASDAQ:ELEV) Critical Survey

Passage Bio (NASDAQ:PASGGet Free Report) and Elevation Oncology (NASDAQ:ELEVGet Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, valuation and risk.

Profitability

This table compares Passage Bio and Elevation Oncology’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Passage Bio N/A -69.34% -54.85%
Elevation Oncology N/A -235.11% -134.01%

Risk and Volatility

Passage Bio has a beta of 1.12, meaning that its share price is 12% more volatile than the S&P 500. Comparatively, Elevation Oncology has a beta of 1.1, meaning that its share price is 10% more volatile than the S&P 500.

Earnings and Valuation

This table compares Passage Bio and Elevation Oncology’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Passage Bio N/A N/A -$136.12 million ($2.06) -0.49
Elevation Oncology N/A N/A -$95.08 million ($5.43) -0.54

Elevation Oncology is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

61.6% of Passage Bio shares are held by institutional investors. Comparatively, 83.7% of Elevation Oncology shares are held by institutional investors. 12.4% of Passage Bio shares are held by insiders. Comparatively, 14.9% of Elevation Oncology shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Passage Bio and Elevation Oncology, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Passage Bio 0 0 3 0 3.00
Elevation Oncology 0 0 4 0 3.00

Passage Bio presently has a consensus target price of $7.00, indicating a potential upside of 600.00%. Elevation Oncology has a consensus target price of $4.83, indicating a potential upside of 66.09%. Given Passage Bio’s higher probable upside, equities analysts plainly believe Passage Bio is more favorable than Elevation Oncology.

Summary

Passage Bio beats Elevation Oncology on 6 of the 10 factors compared between the two stocks.

About Passage Bio

(Get Free Report)

Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. Passage Bio, Inc. has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

About Elevation Oncology

(Get Free Report)

Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in New York, New York.

Receive News & Ratings for Passage Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Passage Bio and related companies with MarketBeat.com's FREE daily email newsletter.